Abstract
Human CD38 is a cell surface molecule endowed with multiple functions. As an enzyme, it catalyzes the production of Ca2+ active metabolites, predominantly cADPR and ADPR. As a receptor, it regulates the activation of an intracellular signaling pathway, generally linked to lymphocyte activation and proliferation in physiological conditions. The finding that CD38 behaves as an independent negative prognostic factor in CLL patients was the starting point for investigations into the functional role of the molecule in the neoplastic context. Data accumulating in over a decade concur to define a model where CD38 is a central element of a large supramolecular complex that includes surface signaling receptors, chemokine receptors, adhesion molecules and matrix metalloproteases. Expression of CD38 within this supramolecular complex makes signal transduction as well as chemotaxis and homing more efficient, suggesting that the molecule is an integrator of proliferative and migratory signals. These data indicate that CD38 is not only a reliable disease marker but also a functional molecule in the CLL context. The next decade will likely tell whether it can also be a useful therapeutic target.
Keywords: Chronic lymphocytic leukemia, CD38, CD31, proliferation, chemotaxis, homing, enzyme, metalloproteases, chemokine, Ca2+
Mini-Reviews in Medicinal Chemistry
Title: CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside?
Volume: 11 Issue: 6
Author(s): S. Deaglio, T. Vaisitti, S. Serra, V. Audrito, C. Bologna, G. D'Arena, L. Laurenti, D. Gottardi and F. Malavasi
Affiliation:
Keywords: Chronic lymphocytic leukemia, CD38, CD31, proliferation, chemotaxis, homing, enzyme, metalloproteases, chemokine, Ca2+
Abstract: Human CD38 is a cell surface molecule endowed with multiple functions. As an enzyme, it catalyzes the production of Ca2+ active metabolites, predominantly cADPR and ADPR. As a receptor, it regulates the activation of an intracellular signaling pathway, generally linked to lymphocyte activation and proliferation in physiological conditions. The finding that CD38 behaves as an independent negative prognostic factor in CLL patients was the starting point for investigations into the functional role of the molecule in the neoplastic context. Data accumulating in over a decade concur to define a model where CD38 is a central element of a large supramolecular complex that includes surface signaling receptors, chemokine receptors, adhesion molecules and matrix metalloproteases. Expression of CD38 within this supramolecular complex makes signal transduction as well as chemotaxis and homing more efficient, suggesting that the molecule is an integrator of proliferative and migratory signals. These data indicate that CD38 is not only a reliable disease marker but also a functional molecule in the CLL context. The next decade will likely tell whether it can also be a useful therapeutic target.
Export Options
About this article
Cite this article as:
Deaglio S., Vaisitti T., Serra S., Audrito V., Bologna C., D'Arena G., Laurenti L., Gottardi D. and Malavasi F., CD38 in Chronic Lymphocytic Leukemia: From Bench to Bedside?, Mini-Reviews in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/138955711795843338
DOI https://dx.doi.org/10.2174/138955711795843338 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes
Current HIV Research Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) Oligonucleotides and Oligonucleotide Conjugates: A New Approach for Cancer Treatment
Current Medicinal Chemistry Study of Cancer Cell Lines with Fourier Transform Infrared (FTIR)/ Vibrational Absorption (VA) Spectroscopy
Current Physical Chemistry Retrospective Observational Study to Evaluate Causality, Preventability and Severity of Adverse Drug Reaction Associated with Anticancer Drugs in a Tertiary Care Hospital in Northern India
Current Drug Safety Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Current Drug Delivery Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology